Independent · Evidence-first

Where's the proof?

The healthtech news that shows its proof.

Global Healthtech Brief is an independent, evidence-first daily briefing on LinkedIn. Every story comes with a plain-English evidence rating, so you can tell a press release from a proven result.

Follow on LinkedIn Subscribe to The Weekly Proof

What you get

News with the evidence attached

Regulatory decisions, funding rounds, deals, launches, research and policy across digital health and medical devices. Short, sourced and honest about what is actually known.

Every weekday

Daily evidence-rated posts

One clear card per story, written to be read in the LinkedIn feed.

The headline fact, without the marketing language
A 1–5 evidence rating from Professor Proof
A one-line summary of what the evidence is
The source, every time

Follow on LinkedIn

Every Friday

The Weekly Proof

A LinkedIn newsletter that rounds up the week that mattered.

The most important stories of the week, in one read
Which claims held up, and which did not
Trends across Europe, the UK and the US
Free, on LinkedIn

Subscribe to The Weekly Proof

The evidence scale

How Professor Proof rates a story

Illustration of Professor Proof, a grey-haired professor in a teal coat holding a magnifying glass — Professor Proof, our resident sceptic.

Each story is scored from 1 to 5 on the strength of the evidence behind it. The rating describes the evidence, not the quality of the product or the company.

Level	Evidence	What it means
1	Company claims only	Announcements and marketing statements with no independent data published.
2	Pilot or observational	Early pilots, single-site studies, case series or observational data.
3	Prospective multicentre or regulator-cleared	A prospective multicentre study, or clearance or approval from a regulator such as the FDA, MHRA or a notified body.
4	Peer-reviewed RCT	At least one randomised controlled trial published in a peer-reviewed journal.
5	Multiple RCTs or meta-analysis, plus real-world adoption	Consistent results across several trials or a meta-analysis, backed by real-world use at scale.

Ratings are an editorial judgement based on publicly available sources at the time of posting. They are not medical, clinical or investment advice.

Samples

Recent cards from the feed

Card: FDA clears Penumbra's CAVT for DVT, evidence level 3 of 5 — **FDA clears Penumbra's CAVT for DVT**Regulatory, US · Evidence 3/5

Card: XRlabs raises $8.4M seed for AI in the operating room, evidence level 1 of 5 — **XRlabs raises $8.4M seed**Funding, UK · Evidence 1/5

Card: FDA clears NeuroXT's MCI prognosis AI, evidence level 3 of 5 — **FDA clears NeuroXT's MCI prognosis AI**Regulatory, 510(k) · Evidence 3/5

Card: HistoIndex and A*STAR sign fibrosis AI pact, evidence level 1 of 5 — **HistoIndex and A*STAR sign fibrosis AI pact**Deals · Evidence 1/5

Read the news. Ask for the proof.

Follow on LinkedIn Subscribe to The Weekly Proof